Pharmaceutical company app embracing blockchain

• Pharmaceutical company app embracing blockchain

The resolution, which currently receives 100% of the vote in favor of Pfizer joining Vitadao, is likely to pass. If so, Pfizer will be announced in mid-October as a stakeholder, and possibly as a future acquirer of any intellectual property emerging from it.

Pfizer's interest represents a shift in the decades-old biotechnology life cycle, one dominated by public research universities and large pharmaceutical giants, both of whom work in tandem to produce many of the drugs we see today.

• Healthcare enters the field of blockchain

It is difficult to say how many decentralized organizations are involved in pharmaceuticals, but Blockchain has long been publicized for its use cases in the healthcare world, especially in patient data.
Most patients do not have access to their entire health history from birth, which makes it difficult for clinicians to accurately assess the full range of allergies or illnesses. So startups have emerged to make it easier to share patient data between different providers, such as a primary care physician who can add to a patient's record without creating their own data.
The Vitadao Group was set up by Molecule, a software platform that recently raised $13 million in seed funding to create the Dow Decentralized Organization that will support a variety of different types of research.